Cinciripini Paul M, Tsoh Janice Y, Wetter David W, Lam Cho, de Moor Carl, Cinciripini Lynn, Baile Walter, Anderson Cheryl, Minna John D
Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston, 77230, USA.
Exp Clin Psychopharmacol. 2005 Nov;13(4):282-92. doi: 10.1037/1064-1297.13.4.282.
In this study, 147 smokers were randomly assigned to receive either venlafaxine or placebo in conjunction with behavioral counseling (9 weekly sessions) and transdermal nicotine replacement therapy (22 mg/day). Patients began medication 2 weeks before quitting and continued for 18 weeks after quitting, with the daily dose titrated from 150 to 225 mg. in response to symptoms of negative affect and relapse. The results showed no main effect of treatment on abstinence. Post hoc analysis revealed that both at the end of treatment and at the 1-year follow-up smokers consuming less than a pack of cigarettes a day benefited from the addition of venlafaxine to the treatment regimen. Venlafaxine also reduced negative affect for all smokers for up to 6 weeks postcessation. The findings suggest that venlafaxine could have some role to play in the treatment of lighter smokers, in addition to the expected benefits of nicotine replacement therapy and behavioral counseling.
在本研究中，147名吸烟者被随机分配接受文拉法辛或安慰剂治疗，并结合行为咨询（共9次，每周1次）和经皮尼古丁替代疗法（22毫克/天）。患者在戒烟前2周开始用药，并在戒烟后持续用药18周，每日剂量根据消极情绪和复吸症状从150毫克滴定至225毫克。结果显示，治疗对戒烟并无主要影响。事后分析表明，在治疗结束时以及1年随访期，每天吸烟少于一包的吸烟者在治疗方案中添加文拉法辛后受益。文拉法辛还能在戒烟后长达6周的时间内减轻所有吸烟者的消极情绪。研究结果表明，除了尼古丁替代疗法和行为咨询的预期益处外，文拉法辛在轻度吸烟者的治疗中可能也发挥着一定作用。
